ASH 2023: Lymphomas and CLL

CE / CME

Key Studies in Lymphomas and CLL: Independent Coverage of ASH 2023

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 06, 2024

Expiration: March 05, 2025

Ian Flinn
Ian Flinn, MD, PhD

Activity

Progress
1 2
Course Completed

References

  1. Wang M, Jurczak W, Trněný M, et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract LBA-2.
  2. Kumar A, Soumerai J, Abramson JS, et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naive, TP53-mutant mantle cell lymphoma. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 738.
  3. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903-1910.
  4. Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37:984-991.
  5. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-1210.
  6. Mosunetuzumab [prescribing information]. South San Francisco, CA: Genentech; 2022.
  7. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055-1065.
  8. Falchi L, Okwali M, Ghione P, et al. Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 604.
  9. ciloleucel A [prescribing information]. Santa Monica, CA: Kite Pharma; 2023.
  10. Tisagenlecleucel [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
  11. Lisocabtagene maraleucel [prescribing information]. Bothell, WA: Bristol-Myers Squibb Company; 2021.
  12. Morschauser F, Dahiya S, Palomba ML, et al. TRANSCEND FL: phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 602.
  13. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare study. J Clin Oncol. 2015;33:2516-2522.
  14. Schuster SJ, Fowler N, Dickinson M, et al. Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 Elara 3-year follow-up. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 601.
  15. Glofitamab [prescribing information]. South San Francisco, CA: Genentech, Inc. ; 2023.
  16. Epcoritamab [prescribing information]. Plainsboro, NJ: Genmab US, Inc.; 2023.
  17. Ayyappan S, Kim WS, Kim TM, et al. Final analysis of the phase 2 ELM-2 Study: odronextamab in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL). Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 436.
  18. Duarte C, Kamdar M. Management considerations for patients with primary refractory and early relapsed diffuse large B-cell lymphoma. Am Soc Clin Oncol Educ Book. 2023;e390802.
  19. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327-e339.
  20. Kim WS, Kim TM, Cho SG, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract 444.
  21. Crombie JL, Matasar M, Topp MS, et al. Odronextamab demonstrates durable complete responses in patients with diffuse large B-cell lymphoma (DLBCL) progressing after CAR-T therapy: Outcomes from the ELM-1 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 4461.
  22. Arnason JE, Brouwer-Visser J, Luminari S, et al. Circulating tumor dna analysis associates with progression-free survival (PFS) with odronextamab monotherapy in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large b-cell lymphoma (DLBCL): identification of minimal residual disease status and high-risk subgroups from the phase 2 ELM-2 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 427.
  23. Avivi I, Kim WS, Ko PS, et al. Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5 Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 438.
  24. Belada D, Falchi L, Leppä S, et al. Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high-risk follicular lymphoma,regardless of POD24 status. Presented at: 2023 International Conference on Malignant Lymphoma (ICML); June 13-17, 2023. Abstract 84.
  25. Yamagishi M, Hori M, Fujikawa D, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29:2321-2337 e2327.
  26. Horwitz SM, Izutsu K, Mehta-Shah N, et al. Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral t-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 302.
  27. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 636.
  28. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
  29. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel (liso-cel) in R/R CLL/SLL: 24-month median follow-up of TRANSCEND CLL 004. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 330.
  30. Pirtobrutinib [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2023.
  31.  Rutherford SC, Li H, Herrera AF, et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage hodgkin lymphoma enrolled on SWOG S1826. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 181. 
  32. Barrett A, Collins GP. Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity. Front Oncol. 2022;12:1017787.
  33. Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;47(17_suppl). Abstract LBA4.
  34. Abramson JS, Straus DJ, Bartlett NL, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C). Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 611.